Plus   Neg

Bayer HealthCare Extends Clinical Investigation Of Xarelto

Bayer HealthCare, a subgroup of Bayer AG (BAYZF.PK,BAYRY.PK,BYR.L) and its development partner Janssen Pharmaceuticals, Inc. announced the initiation of the CALLISTO Clinical Research Programme to explore the potential benefits of the oral Factor Xa inhibitor Xarelto (rivaroxaban) for the prevention and treatment of pulmonary embolism and deep vein thrombosis in patients with various types of cancer.

In patients with active cancer, the risk of VTE is four to seven times higher than in people of the same age without cancer. And importantly, chemotherapy significantly increases the risk further by up to 6.5 times. Despite this, none of the current Clinical Guidelines recommend the routine use of VTE prevention in most ambulatory cancer patients. Regarding the use of anticoagulation therapy for the treatment and secondary prevention of VTE, current Clinical Guideline recommendations are based on few and small clinical trials.

The CALLISTO Programme is a multi-trial prospective clinical research initiative aimed at generating new evidence to help manage cancer-associated thrombosis (CAT). The Programme will consist of nine initiatives in total, comprising both clinical studies and Registries, and will involve more than 4,000 patients worldwide.

The CALLISTO Clinical Research Programme will add to the overall investigation of rivaroxaban, which - by the time of its completion - is expected to include more than 275,000 patients in both clinical trials and real world settings.

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto. Xarelto is approved for seven indications, protecting patients across more venous and arterial thromboembolic (VAT) conditions than any other novel oral anticoagulant.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices. Shares of Daimler AG were gaining around 2 percent in the morning trading in Germany after the auto giant reported Friday higher profit in its third-quarter, despite weakness in revenues and sales volume. Further, the company now expects Group EBIT for full year 2020 at the prior-year level, compared to previous expectation of a decline. Retailer Bed Bath & Beyond Inc. is recalling SALT Lounge Chairs citing fall risks, the U.S. Consumer Product Safety Commission announced. The recall involves about 10,000 units sold in the United States and about 330 sold in Canada. The chairs were manufactured in China, and imported by Liberty Procurement Co. Inc., an affiliate of Bed Bath & Beyond.
Follow RTT